Research: RACINE and COLLEAGUES,

Listed in Issue 222

Abstract

RACINE and COLLEAGUES,  (1)1] Department of Gastroenterology, University Hospital of Bicêtre, Assistance Publique Hôpitaux de Paris, Université Paris-Sud, Le Kremlin Bicêtre, France [2]  INSERM, UMRS 1018, Team 9, Centre for Research in Epidemiology and Population Health, Institut Gustave Roussy, Université Paris-Sud, Villejuif, France.

(2)Caisse Nationale de l'Assurance Maladie des Travailleurs Salariés, Paris, France.

(3)INSERM, UMRS 1018, Team 9, Centre for Research in Epidemiology and Population Health, Institut Gustave Roussy, Université Paris-Sud, Villejuif, France.

(4)Department of Dermatology, Hôpital Henri-Mondor, Assistance Publique Hôpitaux de  Paris, Université Paris Est Créteil Val de Marne, Créteil, France examined the association between isotretinoin use and risk for UC and Crohn's disease (CD)by conducting a large nationwide case-control study in France.

Background

Isotretinoin, a drug widely prescribed for severe acne, has been suspected to increase the risk of ulcerative colitis (UC), but data are conflicting. To further examine the association between isotretinoin use and risk for UC and Crohn's disease (CD), the authors conducted a large nationwide case-control study in France.

Methodology

The authors used information from the National Health Insurance system for all French people covered by the general scheme between 1 January 2008 and 31 December 2010, totaling over 50 million individuals (i.e., 76% of the whole French population). All incident claims for UC and CD and all medical drug reimbursements were automatically recorded in the database. For each case, four controls were matched on age, gender, year of enrollment, and follow-up duration. The association between isotretinoin use and UC or CD claim was estimated by conditional logistic regression.

Results

The authors included 7,593 cases of inflammatory bowel disease (IBD; 3,187 UC, 4,397 CD, and 9 indeterminate colitis) and 30,372 controls; among them, 26 cases (0.3%) (15 UC (0.5%) and 11 CD (0.3%)) and 140 controls (0.4%) were exposed to isotretinoin. Isotretinoin exposure was not associated with an increased risk for UC (odds ratio (OR)=1.36 (95% confidence intervals (CI): 0.76, 2.45)) but was associated with a decreased risk for CD (OR=0.45 (95% CI: 0.24, 0.85)), P value for homogeneity between UC and CD=0.001. Results were similar in analyses restricted to individuals below the age of 40 years, to cases with colonoscopy or intestinal surgery, or when adjusting for other acne treatments.

Conclusion

In this population-based case-control study, isotretinoin use was not associated with increased UC risk but was associated with a decreased CD risk. This study provides reassuring data for people using isotretinoin.

References

Racine A(1), Cuerq A(2), Bijon A(3), Ricordeau P(2), Weill A(2), Allemand H(2), Chosidow O(4), Boutron-Ruault MC(3), Carbonnel F(1). Am J Gastroenterol. Isotretinoin and risk of inflammatory bowel disease: a French nationwide study.;109(4):563-9. doi: 10.1038/ajg.2014.8. Epub Feb 18 2014. Apr 2014. Comment in  Am J Gastroenterol. 109(4):570-1. 2014 Apr.   Rev Prat. 64(6):769. Jun 2014.

Munro Hall Clinic 2019

IJCA 2018 New Skyscraper

Scientific and Medical Network 2

Cycle India 2020

Walk on the Wide Side Trek Kenya 2020

Big Heart Bike Ride South Africa 2020

top of the page